Literature DB >> 29264954

Mechanisms of right heart disease in pulmonary hypertension (2017 Grover Conference Series).

Kewal Asosingh1, Serpil Erzurum1,2.   

Abstract

Current dogma is that pathological hypertrophy of the right ventricle is a direct consequence of pulmonary vascular remodeling. However, progression of right ventricle dysfunction is not always lung-dependent. Increased afterload caused by pulmonary vascular remodeling initiates the right ventricle hypertrophy, but determinants leading to adaptive or maladaptive hypertrophy and failure remain unknown. Ischemia in a hypertrophic right ventricle may directly contribute to right heart failure. Rapidly enlarging cardiomyocytes switch from aerobic to anaerobic energy generation resulting in cell growth under relatively hypoxic conditions. Cardiac muscle reacts to an increased afterload by over-activation of the sympathetic system and uncoupling and downregulation of β-adrenergic receptors. Recent studies suggest that β blocker therapy in PH is safe, well tolerated, and preserves right ventricle function and cardiac output by reducing right ventricular glycolysis. Fibrosis, an evolutionary conserved process in host defense and wound healing, is dysregulated in maladaptive cardiac tissue contributing directly to right ventricle failure. Despite several mechanisms having been suggested in right heart disease, the causes of maladaptive cardiac remodeling remain unknown and require further research.

Entities:  

Keywords:  fibrosis; pulmonary arterial hypertension; right ventricle function and dysfunction

Year:  2017        PMID: 29264954      PMCID: PMC5798686          DOI: 10.1177/2045893217753121

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  75 in total

1.  Right ventricular oxygen supply parameters are decreased in human and experimental pulmonary hypertension.

Authors:  Gerrina Ruiter; Yeun Ying Wong; Frances S de Man; M Louis Handoko; Richard T Jaspers; Pieter E Postmus; Nico Westerhof; Hans W M Niessen; Willem J van der Laarse; Anton Vonk-Noordegraaf
Journal:  J Heart Lung Transplant       Date:  2012-11-09       Impact factor: 10.247

2.  Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

Authors:  Samar Farha; Didem Saygin; Margaret M Park; Hoi I Cheong; Kewal Asosingh; Suzy Aa Comhair; Olivia R Stephens; Emir C Roach; Jacqueline Sharp; Kristin B Highland; Frank P DiFilippo; Donald R Neumann; W H Wilson Tang; Serpil C Erzurum
Journal:  JCI Insight       Date:  2017-08-17

3.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.

Authors:  Mariëlle C van de Veerdonk; Taco Kind; J Tim Marcus; Gert-Jan Mauritz; Martijn W Heymans; Harm-Jan Bogaard; Anco Boonstra; Koen M J Marques; Nico Westerhof; Anton Vonk-Noordegraaf
Journal:  J Am Coll Cardiol       Date:  2011-12-06       Impact factor: 24.094

4.  Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension.

Authors:  Lin Piao; Yong-Hu Fang; Kishan Parikh; John J Ryan; Peter T Toth; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2013-06-21       Impact factor: 4.599

5.  Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart.

Authors:  Stine Andersen; Jacob Gammelgaard Schultz; Asger Andersen; Steffen Ringgaard; Jan M Nielsen; Sarah Holmboe; Mads D Vildbrad; Frances S de Man; Harm J Bogaard; Anton Vonk-Noordegraaf; Jens Erik Nielsen-Kudsk
Journal:  J Card Fail       Date:  2014-08-15       Impact factor: 5.712

6.  Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats.

Authors:  L Brown; J Miller; A Dagger; C Sernia
Journal:  J Cardiovasc Pharmacol       Date:  1998-01       Impact factor: 3.105

Review 7.  Origins of cardiac fibroblasts.

Authors:  Elisabeth M Zeisberg; Raghu Kalluri
Journal:  Circ Res       Date:  2010-11-26       Impact factor: 17.367

8.  Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year.

Authors:  Erika L Lundgrin; Margaret M Park; Jacqueline Sharp; W H Wilson Tang; James D Thomas; Kewal Asosingh; Suzy A Comhair; Frank P DiFilippo; Donald R Neumann; Laura Davis; Brian B Graham; Rubin M Tuder; Iva Dostanic; Serpil C Erzurum
Journal:  Ann Am Thorac Soc       Date:  2013-02

Review 9.  Cardiac interstitium in health and disease: the fibrillar collagen network.

Authors:  K T Weber
Journal:  J Am Coll Cardiol       Date:  1989-06       Impact factor: 24.094

10.  CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis.

Authors:  Po-Yin Chu; Ken Walder; Duncan Horlock; David Williams; Erin Nelson; Melissa Byrne; Karin Jandeleit-Dahm; Paul Zimmet; David M Kaye
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

View more
  5 in total

1.  Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Bi-Xi Chen; Hai-Qun Xing; Juan-Ni Gong; Xiao-Juan Guo; Xiao-Ying Xi; Yuan-Hua Yang; Li Huo; Min-Fu Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

2.  A unique gut microbiota signature in pulmonary arterial hypertension: A pilot study.

Authors:  Arun Jose; Senu Apewokin; Walaa E Hussein; Nicholas J Ollberding; Jean M Elwing; David B Haslam
Journal:  Pulm Circ       Date:  2022-02-28       Impact factor: 2.886

Review 3.  Metabolism in Pulmonary Hypertension.

Authors:  Weiling Xu; Allison J Janocha; Serpil C Erzurum
Journal:  Annu Rev Physiol       Date:  2021-02-10       Impact factor: 19.318

4.  Single-cell transcriptomic profile of human pulmonary artery endothelial cells in health and pulmonary arterial hypertension.

Authors:  Kewal Asosingh; Suzy Comhair; Lori Mavrakis; Weiling Xu; Dean Horton; Ian Taylor; Svyatoslav Tkachenko; Bo Hu; Serpil Erzurum
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

5.  Right ventricular myocardial oxygen tension is reduced in monocrotaline-induced pulmonary hypertension in the rat and restored by myo-inositol trispyrophosphate.

Authors:  Claudine Kieda; Michał Mączewski; Marta Oknińska; Zuzanna Zambrowska; Karolina Zajda; Aleksandra Paterek; Klaudia Brodaczewska; Urszula Mackiewicz; Cezary Szczylik; Adam Torbicki
Journal:  Sci Rep       Date:  2021-09-09       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.